MX2023004275A - Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. - Google Patents
Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.Info
- Publication number
- MX2023004275A MX2023004275A MX2023004275A MX2023004275A MX2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A
- Authority
- MX
- Mexico
- Prior art keywords
- bispecific antibodies
- antigen
- binding protein
- protein constructs
- binding
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta divulgación se refiere a constructos de proteína de unión a antígeno (por ejemplo, anticuerpos biespecíficos o fragmentos de unión a antígeno de los mismos), en donde los constructos de proteína de unión a antígeno se unen específicamente a dos antígenos diferentes (por ejemplo, PD-1 y CD40).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020120918 | 2020-10-14 | ||
CN2021085335 | 2021-04-02 | ||
PCT/CN2021/123438 WO2022078357A1 (en) | 2020-10-14 | 2021-10-13 | Anti-pd-1/cd40 bispecific antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023004275A true MX2023004275A (es) | 2023-05-02 |
Family
ID=81207517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004275A MX2023004275A (es) | 2020-10-14 | 2021-10-13 | Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230220082A1 (es) |
EP (1) | EP4229096A4 (es) |
JP (1) | JP2023545521A (es) |
KR (1) | KR20230092932A (es) |
CN (1) | CN116390755A (es) |
AU (1) | AU2021359495A1 (es) |
BR (1) | BR112023006989A2 (es) |
CA (1) | CA3197463A1 (es) |
IL (1) | IL302042A (es) |
MX (1) | MX2023004275A (es) |
WO (1) | WO2022078357A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117624372A (zh) * | 2022-08-26 | 2024-03-01 | 北京天广实生物技术股份有限公司 | 靶向cd40和pd-l1的抗体及其用途 |
CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
WO2024059901A1 (en) * | 2022-09-20 | 2024-03-28 | Currus Biologics Pty Ltd | A method of rescuing exhausted immune cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017353852A1 (en) * | 2016-11-02 | 2019-05-23 | Apexigen, Inc. | Anti-CD40 antibodies in combination and methods of use |
CA3091502A1 (en) * | 2018-02-23 | 2019-08-29 | Eucure (Beijing) Biopharma Co., Ltd | Anti-pd-1 antibodies and uses thereof |
CA3105875A1 (en) * | 2018-07-20 | 2020-01-23 | Eucure (Beijing) Biopharma Co., Ltd | Anti-cd40 antibodies and uses thereof |
WO2020102233A1 (en) * | 2018-11-13 | 2020-05-22 | Jn Biosciences Llc | Bispecific antibodies for activation of immune cells |
CN116057070A (zh) * | 2019-10-23 | 2023-05-02 | 礼进生物医药科技(上海)有限公司 | 抗cd40结合分子和包括其的双特异性抗体 |
-
2021
- 2021-10-13 JP JP2023523084A patent/JP2023545521A/ja active Pending
- 2021-10-13 KR KR1020237014700A patent/KR20230092932A/ko unknown
- 2021-10-13 CN CN202180069673.0A patent/CN116390755A/zh active Pending
- 2021-10-13 WO PCT/CN2021/123438 patent/WO2022078357A1/en active Application Filing
- 2021-10-13 IL IL302042A patent/IL302042A/en unknown
- 2021-10-13 EP EP21879400.6A patent/EP4229096A4/en active Pending
- 2021-10-13 AU AU2021359495A patent/AU2021359495A1/en active Pending
- 2021-10-13 CA CA3197463A patent/CA3197463A1/en active Pending
- 2021-10-13 MX MX2023004275A patent/MX2023004275A/es unknown
- 2021-10-13 BR BR112023006989A patent/BR112023006989A2/pt unknown
-
2023
- 2023-01-05 US US18/150,428 patent/US20230220082A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230092932A (ko) | 2023-06-26 |
CN116390755A (zh) | 2023-07-04 |
BR112023006989A2 (pt) | 2024-01-02 |
JP2023545521A (ja) | 2023-10-30 |
IL302042A (en) | 2023-06-01 |
EP4229096A1 (en) | 2023-08-23 |
EP4229096A4 (en) | 2024-06-12 |
AU2021359495A1 (en) | 2023-04-13 |
WO2022078357A1 (en) | 2022-04-21 |
US20230220082A1 (en) | 2023-07-13 |
CA3197463A1 (en) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021007320A (es) | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor. | |
MX2023004275A (es) | Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. | |
JOP20200078A1 (ar) | أجسام مضادة خاصة بـ cd47 وpd-l1 | |
WO2018217940A3 (en) | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same | |
EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
MD3353212T2 (ro) | Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora | |
EP4248996A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
AU2017297138A8 (en) | Anti-PD-1 antibodies, method for producing same and method for using same | |
MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
MY194994A (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
EP3786183A3 (en) | Antigen binding constructs to cd3 | |
EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
MX2022006578A (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos. | |
WO2018194496A3 (ru) | Моноклональное антитело к pd-l1 | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
AU2019433019A8 (en) | Antibodies binding CD40 and uses thereof | |
JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
MX2023014458A (es) | Anticuerpos anti-ccr8 y usos de los mismos. | |
MX2021009275A (es) | Moleculas de union especificas. | |
MX2022003833A (es) | Anticuerpos anti-kir3dl3 y sus usos. | |
WO2023004477A8 (en) | Neutralising antibodies and uses thereof |